Our Products

Overview

Our technology is based on a family of novel organic compounds that have potent anti-biofilm properties. The molecular architecture of the compounds is highly tunable for addressing specific needs in a diverse array of product markets. The molecules are soluble in paint and have excellent solubility in water and other biologically relevant liquids.

Our products are unique for four fundamental reasons.

  1. They are the only product consisting of small organic molecules that have been shown to disperse pre-formed biofilms. This is significant because in clinical and most industrial settings, biofilms have already formed. Therefore, the only option for remediation and treatment is biofilm disruption.
  2. Our molecules have been shown to be non-toxic by cellular assays run by a federal toxicology laboratory. This is crucial because we can pursue the use of these molecules in clinical settings.
  3. Our molecules are extremely stable. We have shown that they are stable in water from pH 4-11 and temperatures up to 100° C; therefore our molecules are applicable to controlling/eliminating bacterial biofilms in industrial settings.
  4. Our molecules are broad acting and applicable to medicine, agriculture, and industry.

Medical Applications

Agile compounds have been tested against the following bacterial biofilms and shown to both inhibit and disperse these biofilms:

Bordetella bronchiseptica (beta proteobacterium): A causative agent of infectious bronchitis, Bordetella bronchiseptica is related to B. pertussis — the obligate human pathogen which causes pertussis or whooping cough, which is responsible for 300,000 deaths/year. Agile's inhibition of this biofilm is significant because we have inhibited across bacterial class (both gamma and beta proteobacteria).

Pseudomonas aeruginosa (gamma proteobacterium): An opportunistic pathogen of immunocompromised individuals, P. aeruginosa typically infects the pulmonary tract, urinary tract, burns, wounds, and also causes other blood infections. It's the most common cause of burn and external ear infections, and is the most frequent colonizer of medical devices (e.g., catheters). Pseudomonas can in rare circumstances cause community-acquired pneumonias as well as ventilator-associated pneumonias, being one of the most common agents isolated in several studies. One in ten hospital-acquired infections is from Pseudomonas. Cystic fibrosis patients are also predisposed to P. aeruginosa infection of the lungs along with cancer patients undergoing chemotherapy and radiation treatment. The most common cause of burn infections is P. aeruginosa. Pseudomonas is also a common cause of post-operative infection in radial keratotomy surgery patients.

Acinetobacter baummanii (gamma proteobacterium): These "multi-drug resistant Acinetobacter baumannii" forms opportunistic infections and are often referred to as MDRAB. Multi-drug resistant strains that are resistant to every antibiotic have been isolated. Acinetobacter enters into the body through open wounds, catheters, and breathing tubes. It usually infects those with compromised immune systems, such as the wounded, the elderly, children or those with immune diseases. There have been many reports of drug-resistant A. baumannii infections among American soldiers wounded in Iraq. Colonized health care workers and hospital visitors can carry the bacteria into neighboring wards and other medical facilities. The number of nosocomial infections (hospital-acquired infections) caused by A. baumannii has increased in recent years causing hospital/ward closures in many cases.

Vibrio vulnificus (gamma proteobacterium): This pathogen causes an infection often incurred after eating seafood, especially oysters; the bacteria can also enter the body through open wounds when swimming or wading in infected waters. Symptoms include vomiting, diarrhea, abdominal pain, and a blistering dermatitis. Severe symptoms and even death can occur if the bacterium enters the bloodstream. This resulted in many deaths following Hurricane Katrina.

Haemophilus influenza (gamma proteobacterium): In infants and young children, H. influenzae type b (Hib) causes bacteremia, and acute bacterial meningitis. Occasionally, it causes cellulitis, osteomyelitis (infection of bone or bone marrow) and joint infections. Hib remains a major cause of lower respiratory tract infections in infants and children in developing countries. Unencapsulated H. influenzae (non-B type) causes ear (otitis media) and eye (conjunctivitis) infections and sinusitis in children, and is associated with pneumonia.

Staphylococcus aureus: A gram positive pathogen that is the prevalent bacterium isolated from hospital acquired infections, Staphylococcus aureus can cause a range of illnesses from minor skin infections, such as pimples, boils, cellulitis folliculitis, furuncles, carbuncles, scalded skin syndrome and abscesses, to life-threatening diseases, such as pneumonia, meningitis, osteomyelitis endocarditis, toxic shock syndrome (TSS), and septicemia. Its incidence is from skin, soft tissue, respiratory, bone, joint, endovascular to wound infections. It is still one of the four most common causes of hospital acquired infection, often causing postsurgical wound infections. Agile's inhibition of this biofilm is significant because we have inhibited both gram-negative and gram-positive bacteria.

Agricultural Applications

Agile's compounds are currently being tested against the following bacterial biofilms:

  • Xanthomonas axonopodis: Citrus canker (most citrus fruits)
  • Erwinia amylovora: Fireblight (apples, pears)
  • Erwinia carotovora: Bacterial soft rot (BSR) (carrot, potato, tomato, leafy greens, squash, onion, green peppers, etc.)
  • Erwinia tracheiphila and Pseudomonas solanacearum: Bacterial wilt (bananas)

Industrial Applications

Agile's compounds have been successfully tested against the bacterial biofilm Halomonas pacifica (gamma proteobacterium). This biofilm causes "microfouling" which leads to the undesirable accumulation of microorganisms, plants, algae, and animals on submerged structures, especially ships' hulls. Individually small, accumulated biofoulers can form enormous masses that severely diminish ships' maneuverability and carrying capacity. Fouling causes huge material and economic costs in maintenance of mariculture, shipping industries, naval vessels, and seawater pipelines. Governments and industry spend more than US $5.7 billion annually to prevent and control marine biofouling.